Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 6, 2017
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), at the 2...
Aug 29, 2017
SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will participate in the following investor conferences in September: Liolios Gateway Conference - Presenting on Wednesday, September 6 at 10:00 a.m. PDT / 1:00 p.m. EDT in San Francisco Wells F...
Aug 22, 2017
SAN DIEGO, Aug. 22, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on Augus...
Jul 31, 2017
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the underwriters of its previously announced underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share have exercised in full their option to purchase an additional 937,500 shares. All of t...
Jul 12, 2017
SAN DIEGO, July 12, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share.  All of the shares are being sold by Arena.  The gross proceeds from the offering are expected to be $150.0 million, ...
Jul 11, 2017
SAN DIEGO, July 11, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering.  Arena expects to grant the underwriters an option to purchase up to an additional $22.5 milli...
Jul 10, 2017
SAN DIEGO, July 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH).  In this 61-patient study, the primary efficacy ...
Jun 29, 2017
SAN DIEGO, June 29, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the completion of a Phase 1 comparative bioavailability study evaluating the pharmacokinetic (PK) profile of extended release (XR) ralinepag compared to the immediate release (IR) formulation in healthy adults. While the IR formulation curren...
Jun 15, 2017
SAN DIEGO, June 15, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 21, at 1:30 p.m. EDT. The conference will take place June 20-21, 2017, at the St...
Jun 14, 2017
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that at the annual meeting of stockholders, held June 13, 2017, stockholders voted to approve a proposal authorizing the Board of Directors of the Company to amend the Company's certificate of incorporation to effect a reverse stock split of Arena's...
Jun 14, 2017
SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the appointment of Jennifer Jarrett to the Company's Board of Directors.  Ms. Jarrett has over 20 years of experience as a senior executive and finance professional in the life sciences industry.  "We are excited to have someone with Jennife...
Jun 1, 2017
SAN DIEGO, June 1, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that members of its senior management team will present a corporate update at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:30am EDT. The conference will take place June 6-9, 2017 at the Grand Hyatt New York in New York City....
May 18, 2017
SAN DIEGO, May 18, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on the treatment of pulmonary arterial hypertension (PAH) in New York City on Thursday, May 25, from 8-9:30 a.m. EDT. The meeting will feature presentations by key opinio...
May 16, 2017
SAN DIEGO, May 16, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) will present detailed Phase 1 data on ralinepag (APD811), the Company's next-generation, oral, selective prostacyclin receptor (IP) agonist intended for the treatment of pulmonary arterial hypertension (PAH), on May 23 at the American Thoracic Society (ATS) 2017 Inte...
Apr 21, 2017
SAN DIEGO, April 21, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of its previously announced underwritten public offering of 69,000,000 shares of its common stock, including 9,000,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters.  All of the shares w...
Apr 17, 2017
SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 60,000,000 shares of its common stock, offered at a price to the public of $1.15 per share.  The gross proceeds from the offering are expected to be $69.0 million, before deducting the underwriting d...
Apr 17, 2017
SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters a 30‑day option to purchase up to an additional 15% of the shares...
Apr 17, 2017
SAN DIEGO, April 17, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced three data presentations on etrasimod (APD334) at ASPET 2017 at Experimental Biology (EB).  The conference is taking place April 22-26 ...
Mar 27, 2017
SAN DIEGO, March 27, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 16th Annual Needham Health...
Mar 20, 2017
SAN DIEGO, March 20, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced the appointment of Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer. D...
Mar 8, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate update at the 27th Annual Oppenheimer Hea...
Feb 14, 2017
SAN DIEGO, Feb. 14, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the appointment of three new members to the company's Board of Directors.  Jayson Dallas, M.D., Oliver Fetzer, Ph.D., and Garry A. Neil, M.D. have joined as independent directors.  The new directors are all international business executives with sign...
Feb 9, 2017
SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) - Inflammatory Bowel Diseases 2017 on Friday, February 17.  The conference is taking...
Jan 4, 2017
SAN DIEGO, Jan. 4, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has amended its BELVIQ® (lorcaserin HCl) marketing and supply agreement with Eisai Co., Ltd. and Eisai Inc. (collectively, "Eisai"). Under the revised agreement, Eisai is acquiring global commercialization rights to BELVIQ, including in t...
Dec 19, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Dec. 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health Surveillance Agency (ANVISA) for BELVIQ® (lorcaserin HCl) for chronic weight manag...
Dec 13, 2016
SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate update at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 9:00am PT. The conference will take place January 9-12, 2017, at the...
Dec 7, 2016
SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has completed enrollment in the ralinepag phase 2 trial.  Ralinepag is an oral, selective IP receptor agonist targeting the prostacyclin pathway for the treatment of pulmonary arterial hypertension (PAH). The study enrolled approximately 60 pa...
Nov 30, 2016
SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that four abstracts will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference on Friday, December 9 at 6:00pm ET.  The conference is taking place December 8-10 at the Walt D...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit Munshi, the Company's President and Chief Executive Officer will present a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 at 1:30pm ET.  The conference will take place November 29-30, 2016 a...
Nov 9, 2016
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Professor Lucie Clapp will present a poster at the American Heart Association (AHA) Scientific Sessions 2016 on Monday, November 14 at 10:45am CT.  The scientific sessions are taking place November 12-16, 2016 in New Orleans, Louisiana at the Ern...
Nov 3, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin HCl) CIV. Hosted by The Obesity Society and the American Society for Metabolic and Bari...
Oct 11, 2016
SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET.  The meeting is taking place October 15-19 in Vienna, Austria.  The dat...
Oct 3, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 3, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss. "With more than 7...
Sep 1, 2016
SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"), an independent, privately-held drug discovery incubator.  Beacon will focus on identifying and advancing molecules targeting G-Protein Coupled Receptors (GCPRs) from concept to clinic leverag...
Aug 15, 2016
SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today.  Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.    "I am excited to have Vince join u...
Jul 19, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 19, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets. The new formulation of lorcaserin will offer...
Jul 14, 2016
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 14, 2016 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the chronic weight management agent VENESPRI® (lorcaserin HCl: U.S. brand name: BELVIQ...
Jun 30, 2016
SAN DIEGO, June 30, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced a strategic shifting of priorities to emphasize its proprietary clinical stage pipeline. The Company also announced the implementation of additional cost reductions to streamline the organization to support its development programs. "We belie...
Jun 15, 2016
SAN DIEGO, June 15, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind will join its management team as Executive Vice President and Chief Financial Officer, effective June 15, 2016.  Mr. Lind will report to Amit D. Munshi, Arena's President and Chief Executive Officer.    "Kevin is an accompli...
Jun 13, 2016
SAN DIEGO, June 13, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic ...
May 9, 2016
SAN DIEGO, May 9, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which ...
Apr 12, 2016
SAN DIEGO, April 12, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from its Phase 1b multiple-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor with potential utility in the treatment of pain. This randomized, double-blind, p...
Jan 12, 2016
INGELHEIM, Germany, and SAN DIEGO, Jan. 12, 2016 /PRNewswire/ -- Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS r...
Jan 7, 2016
SAN DIEGO, Jan. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time), at The Westin St. Francis Hotel in San Fr...
Dec 1, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Dec. 1, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight countries. The CAMELLIA-TIMI 61 outcomes study is designed to evaluate the impact of long-term...
Nov 30, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 30, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended release formulation of lorcaserin. If approved, the extended release formulation will offe...
Nov 24, 2015
SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace Hotel in New Yo...
Nov 19, 2015
SAN DIEGO, Nov. 19, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company will host an Analyst & Investor Day on Thursday, December 3, 2015, from 12:00 p.m. to 3:00 p.m. Eastern Time (9:00 a.m. to 12:00 p.m. Pacific Time) in New York City. The event will focus on Arena's internally discovered resear...
Nov 2, 2015
WOODCLIFF LAKE, N.J., and SAN DIEGO, Nov. 2, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that six posters regarding lorcaserin HCl data will be presented during ObesityWeekSM. Hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery, the meeting is taking place Nov...
Oct 29, 2015
SAN DIEGO, Oct. 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 1b multiple-ascending dose clinical trial of APD371, a selective and potent agonist of the cannabinoid 2 (CB2) receptor. This randomized, double-blind, placebo-controlled Phase 1b clinical trial will...
Oct 27, 2015
SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on: ...
Oct 27, 2015
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 27, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Patent and Trademark Office granted Arena US Patent No. 9,169,213, entitled "Method of Weight Management," covering BELVIQ® (lorcaserin HCl) for chronic weight management. "This patent ...
Oct 5, 2015
SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that, at the request of the Board of Directors, Jack Lief, Arena's President and Chief Executive Officer, has retired from the company, including its Board of Directors. Dr. Harry F. Hixson, a director of Arena since 2004, has been appointed to serve ...
Sep 24, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Sept. 24, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that lorcaserin HCl data will be presented at the following medical meetings: 2015 Annual Meeting of the American College of Clinical Pharmacology, taking place September 27-29, 2015, in San Francis...
Sep 3, 2015
SAN DIEGO, Sept. 3, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Wells Fargo 2015 Healthcare Conference on Wednesday, September 9, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at the Hyatt Regency in Boston, Massachusetts...
Jul 29, 2015
SAN DIEGO, July 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis. Discovered by Arena, APD334 is an oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic po...
Jun 16, 2015
SAN DIEGO, June 16, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue another opportunity in the biotechnology industry. Mr. Hoffman is expected to remain in hi...
Jun 4, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, June 4, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the following poster regarding lorcaserin HCl will be presented at American Diabetes Association's 75th Scientific Sessions taking place June 5-9, 2015, in Boston, Massachusetts: Impact of ...
May 26, 2015
SAN DIEGO, May 26, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time), at the Grand Hyatt in New York, New York. ...
May 14, 2015
WOODCLIFF LAKE, N.J., and SAN DIEGO, May 14, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that lorcaserin HCl data will be presented at the following medical meetings: American Thoracic Society International Conference taking place in Denver, Colorado, May 15-20, 2015Lorcaserin for Smokin...
May 11, 2015
SAN DIEGO, May 11, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Ro...
May 8, 2015
SAN DIEGO, May 8, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015, at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time), at the Encore at the Wynn in Las ...
Apr 29, 2015
SAN DIEGO, April 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced favorable results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent agonist of the cannabinoid 2 (CB2) receptor currently in development for the treatment of pain and potentially fibrotic diseases. T...
Apr 10, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Calif., April 10, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as comp...
Apr 9, 2015
SAN DIEGO, April 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 12:50 p.m. Eastern Time (9:50 a.m. Pacific Time), at the Westin Grand Central Hotel in New York...
Apr 7, 2015
SAN DIEGO and WOODCLIFF LAKE, N.J., April 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc., announced today that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ® (lorcaserin HCl), a serotonin...
Feb 18, 2015
SAN DIEGO, Feb. 18, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 2015 RBC Capital Markets Healthcare Conference on Tuesday, February 24, 2015, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The New York Palace Hotel in New Yor...
Feb 3, 2015
SAN DIEGO, Feb. 3, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ® (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea u...
Feb 2, 2015
SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time), at The Waldorf Astoria in New York City. ...
Jan 21, 2015
SAN DIEGO, Jan. 21, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has sold 21,000,000 shares of common stock to Jefferies LLC and Piper Jaffray & Co. as underwriters for its previously announced public offering. The underwriters offered the shares to purchasers in transactions on The NASDAQ Global Select Ma...
Jan 20, 2015
SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares are being offered by Arena. Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.  ...
Jan 12, 2015
SAN DIEGO, Jan. 12, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). "An intriguing component of this compoun...
Jan 9, 2015
SAN DIEGO, Jan. 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.'s updated BELVIQ® marketing program with targeted new initiatives to address payers, patients and physicians. Encouraged by the increasing number of payers who have made the decision to provide formulary coverage for BELVIQ, E...
Jan 7, 2015
SAN DIEGO, Jan. 7, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from a Phase 1b multiple ascending dose clinical trial for APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. In the Phase 1b cl...
Jan 6, 2015
SAN DIEGO, Jan. 6, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time), at The Westin St. Francis Hotel in San Fr...
Nov 25, 2014
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled "Modulators of the Prostacyclin (PGI2) Receptor Useful for the Treatment of Disorders Related Thereto," covering ralinepag (formerly APD811), an orally availabl...
Nov 24, 2014
SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace Hotel in New York...
Nov 13, 2014
SAN DIEGO, Nov. 13, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York. A li...
Nov 6, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, ta...
Nov 5, 2014
SAN DIEGO, Nov. 5, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona....
Nov 3, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing...
Oct 31, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 31, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during ObesityWeekSM hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery. The meeting is taking place Nov...
Oct 28, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 28, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the...
Oct 13, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 13, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place October 12-15, 2014, in ...
Sep 22, 2014
SAN DIEGO, Sept. 22, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the NewsMakers in the Biotech Industry conference on Friday, September 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time), at the Millennium Broadway Hotel in New...
Sep 2, 2014
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension. "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and clinical data submiss...
Jul 30, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 30, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes...
Jul 29, 2014
WOODCLIFF LAKE, N.J. and SAN DIEGO, July 29, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ® (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated ...
Jul 21, 2014
SAN DIEGO, July 21, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ® (lorcaserin HCl) with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limite...
Jul 15, 2014
SAN DIEGO, July 15, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2). Arena is exploring several potential indications f...
Jul 10, 2014
SAN DIEGO, July 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales f...
Jun 13, 2014
SAN DIEGO, June 13, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, 2014, at 2:25 p.m. Eastern Time (11:25 a.m. Pacific Time), at the InterContinental Hotel in Boston, Massachu...
Jun 3, 2014
SAN DIEGO, June 3, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune dis...
May 27, 2014
SAN DIEGO, May 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the Grand Hyatt in New York, New York. A live audi...
May 9, 2014
SAN DIEGO, May 9, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Eisai ex...
Apr 14, 2014
SAN DIEGO, April 14, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many peop...
Feb 12, 2014
SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing authorization of BELVIQ® as a treatment for chronic weight management with the Brazilian Health Surveillance Agency (Anvisa). In connection with the filing, Arena...
Feb 10, 2014
SAN DIEGO, Calif., Feb. 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exc...
Feb 5, 2014
SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor conferences at The Waldorf Astoria in New York City: 16th Annual BIO CEO & Investor ConferencePresentation: February 11, 2014, at 9:30 a.m. Eastern Time ...
Jan 6, 2014
SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) at The Westin St. Francis Hotel in San Francisco, Califo...
Nov 27, 2013
SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at The New York Palace Hotel in New York City. ...
Nov 18, 2013
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a new data analysis from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the American Heart Association 2013 Scientific Sessions, November 16-20 in Dallas, Texas.  ...
Nov 7, 2013
SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its ...
Oct 15, 2013
SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. will increase its BELVIQ® sales force to approximately 400 representatives by December 2013, doubling the size of the sales force from when BELVIQ became available in June 2013. The expansion of the sales force, which has c...
Sep 23, 2013
SAN DIEGO, Sept. 23, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview, including a BELVIQ® (lorcaserin HCl) CIV launch update, at the NewsMakers in the Biotech Industry conference on Friday, September 27, 2013, at 11:30 a.m. Eastern Time (8:30 a.m. Pac...
Sep 18, 2013
SAN DIEGO, Sept. 18, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)Barcelona, Spain: September...
Sep 16, 2013
SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided an update on Eisai Inc.'s marketing activities for BELVIQ® (lorcaserin HCl) as the US launch campaign enters its consumer phase. Beginning this month, full-page announcements communicating the availability of BELVIQ are being placed in ma...
Sep 6, 2013
SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference on Friday, September 13, 2013, at 1:45 p.m. British Summer Time (5:45 a.m. Pacific Time), at the Bank of America Merrill L...
Aug 28, 2013
SAN DIEGO, Aug. 28, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 ...
Jul 25, 2013
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that BELVIQ® (lorcaserin HCl) has been nominated for the 2013 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults. The Pr...
Jul 25, 2013
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement with CY Biotech Company Ltd. (CYB) for BELVIQ® (lorcaserin HCl) in Taiwan. Under the agreement, Arena granted CYB the righ...
Jun 26, 2013
SAN DIEGO, June 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission (NDS) for BELVIQ™ (lorcaserin HCl) with Health Canada. BELVIQ is being evaluated in Canada as an adjunct to a reduced-calorie di...
Jun 20, 2013
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, June 20, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: American Diabetes Association's 73rd Scientific SessionsChicago: J...
Jun 14, 2013
WOODCLIFF LAKE, N.J. and SAN DIEGO, June 14, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: ENDO 2013, the Endocrine Society's 95th Annual Meeting & ExpoSan Fr...
Jun 14, 2013
SAN DIEGO, June 14, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2013 Wells Fargo Securities Healthcare Conference on Wednesday, June 19, 2013, at 2:25 p.m. Eastern Time (11:25 a.m. Pacific Time), at the InterContinental Hotel in Boston, Massachu...
Jun 7, 2013
SAN DIEGO, June 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported today on the launch of BELVIQ (pronounced BEL-VEEK) in the United States. BELVIQ will be available to patients by prescription in US pharmacies beginning June 11. Eisai Inc. is responsible for the marketing and distribution of BELVIQ under its agreement with...
May 24, 2013
SAN DIEGO, May 24, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the following investor conferences: Deutsche Bank Securities 38th Annual Health Care ConferencePresentation: May 30, 2013, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) ...
May 10, 2013
SAN DIEGO, May 10, 2013  /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time), at the Encore at the Wynn Las Vegas Hotel i...
May 7, 2013
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be eff...
Apr 5, 2013
SAN DIEGO, April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. This randomized, double-blind an...
Apr 1, 2013
SAN DIEGO, April 1, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios S. de R.L. de C.V., a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for BELVIQ® (lorcaserin HCl) in Mexico with the Federal Commission for the Protection Against Sanitary Risk (COFEPR...
Feb 27, 2013
SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The Boston Marriott Copley Place in Boston,...
Feb 6, 2013
SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor conferences at The Waldorf Astoria in New York City: 15th Annual BIO CEO & Investor ConferencePresentation: February 12, 2013, at 1:30 p.m. Eastern Time ...
Jan 2, 2013
SAN DIEGO, Jan. 2, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013, at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's ...
Dec 6, 2012
SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012, at 9:25 a.m. Eastern Time (6:25 a.m. Pacific Time) at The Waldorf Astoria in New York City. A li...
Nov 28, 2012
SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has entered into a co-development and license agreement with Ildong Pharmaceutical Co., Ltd., for temanogrel, Arena's internally discovered inverse agonist of the serotonin 2A receptor. The agreement grants Ildong exclusive rights to commerci...
Nov 21, 2012
SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 24th Annual Healthcare Conference on Wednesday, November 28, 2012, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at The New York Palace Hotel in New York City. Jack Lief, Arena's Pres...
Nov 8, 2012
SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor conferences: Lazard Capital Markets 9th Annual Healthcare ConferencePresentation: November 13, 2012, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) ...
Nov 6, 2012
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd., for BELVIQ® (lorcaserin HCl). Under the agreement, Arena granted Ildong exclusive rights to mark...
Oct 12, 2012
SAN DIEGO, Oct. 12, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH). This randomiz...
Sep 18, 2012
SAN DIEGO, Sept. 18, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the UBS Global Life Sciences Conference on Thursday, September 20, 2012, at 7:30 a.m. Eastern Time (4:30 a.m. Pacific Time) at the Grand Hyatt New York in New York City. A live...
Aug 30, 2012
SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present corporate updates at the following three upcoming investor conferences: Stifel Nicolaus Healthcare ConferencePresentation: September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at th...
Jul 30, 2012
WOODCLIFF LAKE, N.J., and SAN DIEGO, July 30, 2012 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride) New Drug Application (NDA) to Eisai. The transfer establishes Eisai as the marketing authorization holder responsible for regulatory activ...
Jul 11, 2012
SAN DIEGO, July 11, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland. The intended indication is as an adjunct to diet and exercise for w...
Jul 9, 2012
SAN DIEGO, July 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Seventh Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012, at 9 a.m. Eastern Time (6 a.m. Pacific Time) at The Peninsula New York Hotel in New York City. Craig M. Audet, Arena's Seni...
Jul 5, 2012
SAN DIEGO, July 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the promotion of Craig M. Audet to the position of Senior Vice President, Operations and Head of Global Regulatory Affairs. In his new role, Audet will serve as an executive officer of the company. Audet, 48, will oversee various operations at ...
Jun 27, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients...
May 21, 2012
SAN DIEGO, May 21, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of an underwritten public offering of 12,650,000 shares of its common stock, including 1,650,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offere...
May 16, 2012
SAN DIEGO, May 16, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock, offered at a price to the public of $5.50 per share. The gross proceeds to Arena from this offering are expected to be $60.5 million, before deducting underwritin...
May 15, 2012
SAN DIEGO, May 15, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms ...
May 10, 2012
SAN DIEGO  and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug can...
May 10, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., May 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcase...
Mar 26, 2012
SAN DIEGO, March 26, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in p...
Mar 2, 2012
SAN DIEGO, March 2, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the filing of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who ar...
Feb 23, 2012
SAN DIEGO, Feb. 23, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Citi 2012 Global Health Care Conference on Wednesday, February 29, 2012, at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President and Chi...
Feb 8, 2012
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, and Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, are scheduled to present a corporate overview and update at two upcoming investor conferences at th...
Feb 1, 2012
SAN DIEGO, and WOODCLIFF LAKE, N.J., Feb. 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified Arena that an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application (NDA) resubmission will be ...
Jan 11, 2012
SAN DIEGO, Jan. 11, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it has agreed to sell 9,953,250 shares of its common stock, at a price of $1.65775 per share, and approximately 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering t...
Jan 10, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for filing and review Arena's resubmission of the New Drug Application (NDA) for lorcaserin. The FDA considers the resubmission a complete, class 2 re...
Jan 5, 2012
SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's...
Jan 3, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 3, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) following review of the lorcaserin New Drug Application (NDA). Lorcaserin is intend...
Dec 8, 2011
SAN DIEGO, Dec. 8, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011, at 10:15 a.m. Eastern Time (7:15 a.m. Pacific Time) at the Waldorf=Astoria in New York City. Jack Lief, Arena's President an...
Nov 23, 2011
SAN DIEGO, Nov. 23, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 23rd Annual Health Care Conference on Wednesday, November 30, 2011, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) at The New York Palace in New York City. Jack Lief, Arena's President...
Sep 26, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., Sept. 26, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical trial program will be presented in poster sessions at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society in Orlando, Florida. Th...
Sep 21, 2011
SAN DIEGO, Sept. 21, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Sixth Annual JMP Securities Healthcare Conference on Tuesday, September 27, 2011, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at The St. Regis New York Hotel in New York City. Jack Lief, Arena's...
Aug 12, 2011
SAN DIEGO, Aug 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Robert E. Hoffman will rejoin Arena on August 29, 2011, as Vice President, Finance and Chief Financial Officer. Mr. Hoffman served in various financial positions with Arena for over 13 years before departing in March to work for a private biophar...
Aug 9, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 9, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today results from a Pathology Working Group's (PWG) re-adjudication of female rat mammary tumor diagnoses from a two-year rat carcinogenicity study of lorcaserin. Arena convened the PWG in response to the lorcaserin ...
Aug 2, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin concentrations in human cerebrospinal fluid (CSF) and plasma and related data analyses. The study was conducted to provide additional data that may be ...
Jul 12, 2011
SAN DIEGO, July 12, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH. The randomized, double-blind and placebo-controlled trial ...
Jun 20, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., June 20, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial will be presented in poster sessions at the American Diab...
May 26, 2011
ISTANBUL, May 26, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on Obesity. The analyses show that lorcaserin caused statistically significant weight loss compared to placebo at one year among ...
May 20, 2011
SAN DIEGO, May 20, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that lorcaserin will be featured in presentations at ECO 2011, the 18th European Congress on Obesity. ECO 2011 will take place May 25-28, 2011, at the Istanbul Convention & Exhibition Centre Lutfi Kirdar in Istanbul, Turkey. The presentations will inc...
May 6, 2011
SAN DIEGO, May 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Bank of America Merrill Lynch 2011 Health Care Conference on Wednesday, May 11, 2011, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada. Ch...
Mar 29, 2011
SAN DIEGO, March 29, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affili...
Mar 10, 2011
SAN DIEGO, March 10, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was issued United States Reissue Patent No. RE42,190 with claims to methods of identifying compounds that modulate the activity of the GPR119 receptor. This invention stems from the discovery by Arena's scientists of the GPR119 receptor, a t...
Feb 10, 2011
SAN DIEGO, Feb. 10, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the resignation of Robert E. Hoffman, Vice President, Finance and Chief Financial Officer. Mr. Hoffman, who has accepted a new position in the healthcare industry, will remain in his current role at Arena until the reporting of the company's year-end...
Feb 9, 2011
SAN DIEGO, Feb. 9, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena's President and ...
Jan 27, 2011
SAN DIEGO, Jan. 27, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of ...
Jan 6, 2011
SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2011, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco, California. Jack Lief, A...
Dec 22, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Dec. 22, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA). "The meeting discussions reinforce our position that we have a path f...
Dec 21, 2010
SAN DIEGO, Dec. 21, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, will host a conference call and webcast tomorrow, Wednesday, December 22, 2010, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to provide an update following the completion of an end-...
Dec 10, 2010
SAN DIEGO, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH. "An orally bioavailable ...
Nov 24, 2010
SAN DIEGO, Nov. 24, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 22nd Annual Health Care Conference on December 1, 2010, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Jack Lief, Arena's President and C...
Nov 9, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met a...
Nov 4, 2010
SAN DIEGO, Nov. 4, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminatin...
Nov 4, 2010
SAN DIEGO, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report third quarter 2010 financial results before the NASDAQ Global Market opens on Tuesday, November 9, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice Presiden...
Oct 23, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 23, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management...
Oct 20, 2010
SAN DIEGO, Oct. 20, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy. The randomized, double-blind and placebo-contr...
Oct 6, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California. Lorcaserin, which Arena discovered and developed, i...
Sep 16, 2010
SAN DIEGO, and WOODCLIFF LAKE, N.J., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potentia...
Sep 13, 2010
SAN DIEGO, Sept. 13, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will host a conference call and webcast on Friday, September 17, 2010, at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) following the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Comm...
Aug 6, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 20...
Aug 6, 2010
SAN DIEGO, Aug. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has agreed to sell a total of 8,955,224 shares of its common stock, at a price of $6.70 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organiz...
Aug 3, 2010
SAN DIEGO, Aug. 3, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time) at the Sheraton New York Hotel & To...
Jul 27, 2010
SAN DIEGO, July 27, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2010 financial results after the NASDAQ Global Market closes on Tuesday, August 3, 2010. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena...
Jul 14, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., July 14, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. today announced that results from the two-year BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial will be published in the July 15, 2010, issue of the New England...
Jul 1, 2010
SAN DIEGO, July 1, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmace...
Jun 26, 2010
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined...
Jun 17, 2010
SAN DIEGO, June 17, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that new data analyses from lorcaserin's pivotal Phase 3 clinical trial program will be presented in poster sessions at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida. The two posters highligh...
Jun 4, 2010
SAN DIEGO, June 4, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company at two upcoming investor conferences in New York City: -- Jefferies 2010 Global Life Sciences Conferen...
Jun 3, 2010
SAN DIEGO, June 3, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization, to provide Arena with approximately $35.5 million through an equity investment. Under the terms of this financing, ...
Jun 2, 2010
SAN DIEGO, June 2, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New...
May 6, 2010
SAN DIEGO, May 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Ninth Annual JMP Securities Research Conference on Tuesday, May 11, 2010, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) at The Ritz-Carlton in San Francisco. Robert E. Hoffma...
Apr 28, 2010
SAN DIEGO, April 28, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Deutsche Bank 35th Annual Health Care Conference on Monday, May 3, 2010, at 11:20 a.m. Eastern Time (8:20 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston. Jack...
Mar 24, 2010
SAN DIEGO, March 24, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy. "There is a nee...
Mar 18, 2010
SAN DIEGO, March 18, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florid...
Mar 8, 2010
SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) at the Boston Marriott Copley Place in Bosto...
Feb 26, 2010
SAN DIEGO, Feb. 26, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA ...
Feb 24, 2010
SAN DIEGO, Feb. 24, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the U...
Feb 4, 2010
SAN DIEGO, Feb. 4, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief...
Jan 4, 2010
SAN DIEGO, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that the company is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Fra...
Dec 23, 2009
SAN DIEGO, Dec 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today Merck and Co., Inc.'s decision (through an affiliate) to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Ar...
Dec 22, 2009
SAN DIEGO, Dec 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss a...
Dec 10, 2009
SAN DIEGO, Dec 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that positive data from a clinical trial evaluating the abuse potential of lorcaserin were presented in a poster session at the 48th Annual Meeting of the American College of Neuropsychopharmacology. Data from the trial dem...
Nov 24, 2009
SAN DIEGO, Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that the company is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the New York Palace Hotel in New York City. Ja...
Oct 27, 2009
WASHINGTON, Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and qua...
Oct 25, 2009
WASHINGTON, Oct 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that data from the pivotal BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) Phase 3 trial demonstrate lorcaserin significantly increased excess weight loss, improved markers of cardiovasc...
Oct 22, 2009
SAN DIEGO, Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that the company is scheduled to provide an overview of the company at two upcoming investor conferences: -- BIOCOM Investor Conference Presentation: Tuesday, October 27, 2009 at 3:30 p.m. Eastern Time ...
Oct 12, 2009
SAN DIEGO, Oct 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announcedtoday that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC. The line-up includes a late-breaking abstract oral presentation ...
Sep 18, 2009
SAN DIEGO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the UBS Global Life Sciences Conference on September 23, 2009 at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Jack Lief, Aren...
Sep 18, 2009
SAN DIEGO, Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today positive, highly significant top-line results from the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM confirms the results previously reported for the BLOOM (Behavi...
Sep 17, 2009
SAN DIEGO, Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast presentation on Friday, September 18, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss top-line results from BLOSSOM (Behavioral modification and LOrcaser...
Sep 3, 2009
SAN DIEGO, September 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2009 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) at the New York Palace Hotel in New Yo...
Jul 30, 2009
SAN DIEGO, July 30, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009 at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time) at the Millennium Broadway Hot...
Jul 29, 2009
SAN DIEGO, July 29, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2009 financial results after the NASDAQ Global Market closes on Monday, August 3, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E....
Jul 8, 2009
SAN DIEGO, July 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 12,500,000 shares of its common stock at a public offering price of $4.17 per share. All of the shares are being offered by Arena. The gross proceeds to Arena, before expenses, fr...
Jul 7, 2009
SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed ...
Jun 18, 2009
SAN DIEGO, June 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. British Summer Time (4:30 am Eastern Time, 1:30 a.m. Pacific Time) at the Andaz Hotel in Lon...
Jun 17, 2009
SAN DIEGO, June 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Arena stockholder, to provide Arena with $100 million in funding through a credit facility...
Jun 6, 2009
NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy o...
Jun 5, 2009
SAN DIEGO, June 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 8th Annual Needham Life Sciences Conference on June 11, 2009 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Robert E....
Jun 1, 2009
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes A...
May 13, 2009
SAN DIEGO, May 13, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 34th Annual Deutsche Bank Health Care Conference on May 19, 2009 at 10:10 a.m. Eastern Time (7:10 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston...
May 5, 2009
SAN DIEGO, May 5, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoff...
Mar 30, 2009
SAN DIEGO, March 30, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight ...
Mar 29, 2009
SAN DIEGO, March 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight a...
Mar 23, 2009
SAN DIEGO, March 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today it has obtained an equity financing commitment of up to $50 million from Azimuth Opportunity Ltd. During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its com...
Feb 18, 2009
SAN DIEGO, Feb 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of a Phase 2 clinical trial of an orally administered niacin receptor agonist drug candidate being developed by Merck & Co., Inc., under its collaboration with Arena to treat atherosclerosis. Agonists o...
Feb 4, 2009
SAN DIEGO, Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 10, 2009 at 1:45 p.m. Eastern Time (10:45 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena's ...
Jan 8, 2009
SAN DIEGO, Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on January 14, 2009 at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. J...
Dec 15, 2008
SAN DIEGO, Dec 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the gluc...
Dec 9, 2008
SAN DIEGO, Dec 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary...
Dec 8, 2008
SAN DIEGO, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host a Research and Development Day on Monday, December 15, 2008, beginning at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Speakers, including Jack Lief, President and Chief Execut...
Dec 8, 2008
SAN DIEGO, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today publication of the Phase 2b clinical trial results of lorcaserin, its novel drug candidate for the treatment of obesity, in the December 4, 2008 issue of Obesity, the official peer reviewed journal of The Obesity ...
Nov 25, 2008
SAN DIEGO, Nov 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 20th Annual Health Care Conference on December 3, 2008 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the New York Palace Hotel in New York Cit...
Oct 29, 2008
SAN DIEGO, Oct 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Oppenheimer 19th Annual Healthcare Conference on November 4, 2008 at 8:40 a.m. Eastern Time (5:40 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Rober...
Oct 22, 2008
SAN DIEGO, Oct 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIOCOM Investor Conference on October 28, 2008 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) at the Hyatt Regency Hotel in La Jolla, California. Jack Lief, Arena's ...
Oct 7, 2008
SAN DIEGO, Oct 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference on October 13, 2008 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York...
Sep 17, 2008
SAN DIEGO, Sept 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the UBS Global Life Sciences Conference on September 23, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Dominic P. Beha...
Aug 28, 2008
SAN DIEGO, Aug 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 4, 2008 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City....
Jul 29, 2008
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2008 financial results after the NASDAQ Global Market closes on Tuesday, August 5, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice Presiden...
Jul 9, 2008
SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the tre...
Jun 12, 2008
SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia in an oral presentation at the SLEEP 2008 22nd Annual Meeting of the Associated Profession...
Jun 6, 2008
SAN DIEGO, June 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) at the...
May 19, 2008
SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at Citigroup's Global Healthcare Conference on May 22, 2008 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) at the Hilton New York Hotel in New York City. Robert E. Hoffman, Arena's Vice Presi...
May 8, 2008
SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Bank of America 2008 Healthcare Conference on May 14, 2008 at 5:20 p.m. Pacific Time (8:20 p.m. Eastern Time) at the Four Seasons Hotel in Las Vegas, Nevada. Dominic P. Behan, Ph.D., Arena'...
May 7, 2008
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Taisho Pharmaceutical Co., Ltd. initiated a Phase 1 clinical trial of a drug candidate under a GPCR-focused partnership with Arena to develop compounds to treat psychiatric disorders. The drug candidate is a novel oral compound inte...
Apr 28, 2008
SAN DIEGO, April 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2008 at 9:50 a.m. Eastern Time (6:50 a.m. Pacific Time) at the Ritz-Carlton in Key Biscayne, Florida. Jack Lief, Arena's Presiden...
Apr 8, 2008
SAN DIEGO, April 8, 2008 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenan...
Mar 17, 2008
SAN DIEGO, March 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that following a planned review by an independent Echocardiographic Data Safety Monitoring Board (EDSMB) it is continuing BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), a pivotal trial evaluating...
Mar 13, 2008
SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide an overview of the company, including its clinical development and discovery programs, at two upcoming investor conferences: Cowen 28th Annual Health Care Conference Presentat...
Feb 6, 2008
SAN DIEGO, Feb 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 12, 2008 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. David A. Wal...
Jan 30, 2008
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008 at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time) at the Grand Hyatt Hotel in New Yor...
Jan 25, 2008
SAN DIEGO, Jan. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of a second generation oral niacin receptor agonist under a collaboration between the companies to discover drugs for the treatment of atherosclerosis and other disorders. T...
Jan 9, 2008
SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive results from a single dose Phase 1a clinical trial of APD791 and the initiation of a multiple dose Phase 1b clinical trial to further evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's inte...
Jan 7, 2008
SAN DIEGO, Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that initial clinical study results for APD668, an oral drug candidate discovered by Arena and being investigated for the treatment of type 2 diabetes under a partnership with Ortho-McNeil Pharmaceutical, Inc., su...
Jan 3, 2008
SAN DIEGO, Jan. 3 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 26th Annual JPMorgan Healthcare Conference on January 9, 2008 at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. Jack Lief, Arena's President and Ch...
Dec 18, 2007
SAN DIEGO, Dec. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it entered into strategic cooperation agreements with Siegfried Ltd., an affiliate of Siegfried Holding AG (SWX: SFZN). The agreements primarily relate to the manufacturing of lorcaserin hydrochloride, which is expected to be nece...
Dec 13, 2007
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for weight management in overweight and obese patients. Known a...
Dec 12, 2007
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Phillip M. Schneider and Randall E. Woods were appointed to its board of directors. Mr. Schneider and Mr. Woods are Arena's seventh and eighth independent directors and bring significant financial and biotechnology industry operat...
Nov 20, 2007
SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it is scheduled to provide an overview of the company, including its clinical development and discovery programs, at two upcoming investor conferences: 19th Annual Piper Jaffray Health Care Conference ...
Nov 3, 2007
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007 at 10:20 a.m. Eastern Time (7:20 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena...
Nov 1, 2007
SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 11,000,000 shares of its common stock at a public offering price of $9.91 per share. All of the shares are being offered by Arena. The underwriters have a 30-day option to purchase up to an addition...
Oct 31, 2007
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 6, 2007 at 12:20 p.m. Eastern Time (9:20 a.m. Pacific Time) at the New York Palace Hotel in New York City. ...
Oct 29, 2007
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIOCOM Investor Conference on November 2, 2007 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) at the Marriott Del Mar Hotel in San Diego, California. Jack Lief, Arena's President and ...
Oct 19, 2007
SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a preliminary prospectus supplement to a shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 10,000,000 shares of its common stock. In connection with thi...
Oct 3, 2007
SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide a corporate overview of its clinical development and discovery programs at two upcoming investor conferences: Natixis Bleichroeder Hidden Gems Conference Presentation...
Sep 26, 2007
SAN DIEGO, Sept. 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has been selected to be one of the inaugural companies in the new NASDAQ® NeuroInsights® Neurotech Index. The NASDAQ NeuroInsights Neurotech...
Sep 25, 2007
SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive preliminary results from its Phase 2 clinical trial of APD125 in patients with chronic insomnia. APD125 is an orally available drug candidate discovered by Arena that is being evaluated in insomnia patients who have difficult...
Sep 17, 2007
SAN DIEGO, Sept. 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the UBS Global Life Sciences Conference on September 24, 2007 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Jack Lief, Arena's President and Chief Exec...
Sep 13, 2007
SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide a corporate overview of its clinical development and discovery programs at four upcoming investor conferences: ThinkEquity Partners' 5th Annual Growth Conference ...
Sep 11, 2007
SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). T...
Sep 5, 2007
SAN DIEGO, Sept 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Bear Stearns 20th Annual Healthcare Conference on September 11, 2007 at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel in New York City. ...
Aug 31, 2007
SAN DIEGO, Aug 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the NewsMakers in the Biotech Industry Conference on September 6, 2007 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) at the Millennium Broadway Hotel in New York C...
Jul 18, 2007
SAN DIEGO, July 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it initiated dosing in a Phase 1 clinical trial evaluating APD791, Arena's orally administered, internally discovered drug candidate intended for the treatment of arterial thrombo-embolic diseases. This Phase 1 trial is planned to...
Jun 8, 2007
SAN DIEGO, June 8, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference on June 12, 2007 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) at the The Ritz-Carlton Laguna N...
Jun 7, 2007
SAN DIEGO, June 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Sixth Annual Needham & Company Biotechnology & Medical Technology Conference on June 13, 2007 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the New ...
Jun 3, 2007
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference on May 9, 2007 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Dominic P. Be...
May 18, 2007
SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at Citigroup's Global Healthcare Conference on May 24, 2007 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Hilton New York Hotel in New York City. Dominic P. Be...
May 3, 2007
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the sale to an affiliate of BioMed Realty Trust, Inc. of three properties owned and occupied by Arena and the assignment to BioMed of an option to purchase a fourth property currently leased and primarily occupied by Arena. Total consid...
Apr 26, 2007
SAN DIEGO, April 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 32nd Annual Deutsche Bank Health Care Conference on May 2, 2007 at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the Mayflower Hotel in Washington, D.C. Dominic P. Behan, Ph.D., A...
Apr 19, 2007
SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 7th Annual Fortis Biotechnology Conference on Wednesday, April 25, 2007 at 10:00 a.m. British Summer Time (5:00 a.m. Eastern Time; 2:00 a.m. Pacific Time) at the Four Seasons Hotel Park ...
Apr 5, 2007
SAN DIEGO, April 5, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Wednesday, April 11, 2007 at 9:45 a.m. Eastern Time (6:45 a.m. Pacific Time) a...
Mar 23, 2007
SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at BioCentury and Thomson Financial's 2007 Future Leaders in the Biotech Industry Conference on Thursday, March 29, 2007 at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at the Millennium Br...
Mar 13, 2007
SAN DIEGO, March 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Lehman Brothers Tenth Annual Healthcare Conference on Monday, March 19, 2007 at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) at the Loews Miami Beach Hotel. Rob...
Mar 7, 2007
SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Cowen and Company 27th Annual Health Care Conference on Tuesday, March 13, 2007 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Boston Marriott Copley Place. William R. Shanaha...
Mar 5, 2007
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it initiated dosing in a Phase 2 clinical trial of APD125 in chronic insomnia patients. APD125 is an orally available drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance ...
Feb 23, 2007
SAN DIEGO, Feb. 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to participate at the Susquehanna International Group's SIGnificant Investment Options in Healthcare Conference on Thursday, March 1, 2007 at the Omni Berkshire Place in New York City. David A. Walsey, Ar...
Feb 21, 2007
SAN DIEGO, Feb. 21 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2006 financial results after the NASDAQ Global Market closes on Wednesday, February 21, 2007. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hof...
Feb 14, 2007
SAN DIEGO, Feb 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2006 financial results after the NASDAQ Global Market closes on Wednesday, February 21, 2007. That same afternoon, Jack Lief, Arena's President and Chief Executive Offi...
Feb 8, 2007
SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on Wednesday, February 14, 2007 at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Dominic P. Behan, Ph.D...
Feb 5, 2007
SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it completed patient enrollment in the first of three planned Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for the treatment of obesity. Known as BLOOM (Behavioral...
Feb 1, 2007
SAN DIEGO, Feb 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference on Wednesday, February 7, 2007 at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time) at ...
Dec 13, 2006
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of a public offering of 13,225,000 shares of its common stock at a public offering price of $13.21 per share, including 1,725,000 shares sold pursuant to the full exercise of an over-allotment option granted to the un...
Dec 8, 2006
SAN DIEGO, Dec 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 11,500,000 shares of its common stock at a public offering price of $13.21 per share. All of the shares are being offered by Arena. The underwriters have a 30-day option ...
Nov 28, 2006
SAN DIEGO, Nov. 28 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it plans to publicly offer 8,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. In connection with this offering, Arena plans to grant ...
Nov 22, 2006
SAN DIEGO, Nov. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present a corporate overview and update of its clinical development and discovery programs at two upcoming investor conferences: Lazard Capital Markets Third Annual Life Scien...
Nov 9, 2006
SAN DIEGO, Nov 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host a Research and Development Day on Thursday, November 9, 2006, beginning at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Jack Lief, President and Chief Executive Officer, Do...
Nov 8, 2006
SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present a corporate overview and update of its clinical development and discovery programs at two upcoming investor conferences: 2006 Annual Stanford Growth Conference - Healthcar...
Nov 2, 2006
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host a Research and Development Day on Thursday, November 9, 2006, beginning at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Jack Lief, President and Chief Executive Officer, Dominic P. Behan, Ph.D., Sen...
Oct 12, 2006
SAN DIEGO, Oct. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company will be presenting at the BIO InvestorForum on Wednesday, October 18, 2006 at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time) at the Palace Hotel in San Francisco. Louis Scotti, Arena's Vice President, Marketing and ...
Sep 27, 2006
SAN DIEGO, Sept 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil Pharmaceutical, Inc. exercised its option to extend the research term for one additional year under the provisions of its partnership with Arena to develop compounds targeting the Glucose-Dep...
Sep 25, 2006
SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that an investigational niacin receptor agonist that was being developed under its partnership with Merck & Co., Inc. to develop drugs for the treatment of atherosclerosis and other disorders is no longer in development for the tr...
Sep 18, 2006
SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company will be presenting at two upcoming investor conferences during which it is scheduled to provide a corporate overview of the company and its clinical development and discovery programs. The conference information is as...
Sep 12, 2006
SAN DIEGO, Sept. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the dosing of the first patient in the first of three planned Phase 3 clinical trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for the treatment of obesity. Known as BLOOM (Behavioral m...
Sep 5, 2006
SAN DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company will be presenting at the Bear Stearns 19th Annual Healthcare Conference on Tuesday, September 12, 2006 at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time) at the Grand Hyatt in New York City. Jack Lief, Arena's Presid...
Aug 14, 2006
SAN DIEGO, Aug 14, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Christine A. White, M.D. was appointed to its board of directors. Dr. White is Arena's seventh independent director and brings significant development and regulatory experience to its board. Dr. ...
Jun 21, 2006
SALT LAKE CITY, June 21 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that it is presenting favorable results from Phase 1 clinical studies of APD125, a novel insomnia compound, today at the 20th Anniversary Meeting of the Associated Professional Sleep Societies (APSS) in Salt Lake City, UT. In the Phase...
Jun 12, 2006
WASHINGTON, June 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Steven Smith, M.D., principal investigator in the study and associate professor and chief, in-patient unit of the Pennington Biomedical Research Center is presenting data from Arena's positive Phase 2b clinical trial of lorcaseri...
Jun 8, 2006
SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company will be presenting at two investor conferences the week of June 12, 2006, during which it is scheduled to present a corporate overview of the company and its clinical development and discovery programs. The conference ...
Jun 6, 2006
SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Steven Smith, M.D., Principal Investigator, Associate Professor and Chief, In-Patient Unit of the Pennington Biomedical Research Center will present Phase 2b data on lorcaserin hydrochloride (formerly APD356) in an oral presentatio...
May 18, 2006
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the Bank of America 2006 Health Care Conference on Wednesday, May 17, 2006, at 3:20 p.m. Pacific Time (6:20 p.m. Eastern Time) at the Four Seasons Hotel in Las Vegas, Nevada. Jack Lief, Arena's President and Chie...
May 18, 2006
SAN DIEGO, May 18, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of a Phase 2 clinical trial of MK-0354, an Arena discovered orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. The Phase 2 ...
May 8, 2006
SAN DIEGO, May 8, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2006 financial results after the NASDAQ National Market closes on Monday, May 8, 2006. That same afternoon Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Ho...
May 5, 2006
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name lorcaserin hydrochloride for APD356, a selective 5-HT2C serotonin receptor agonist under investigation for the treatment of obesity. Lorcaserin hyd...
Apr 19, 2006
SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, April 25, 2006, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Jack Lief, Arena's President and Ch...
Mar 31, 2006
SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceutical Conference on Wednesday, April 5, 2006, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) at the Millennium Broadway Hotel in New York C...
Mar 29, 2006
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today updates on its clinical programs for APD356, being developed for the treatment of obesity, and APD125, being developed for the treatment of insomnia. APD356 (Obesity) Clinical Program Update Arena recently recei...
Mar 27, 2006
SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the BioCentury Future Leaders in the Biotech Industry Conference on Thursday, March 30, 2006, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the Millennium Broadway Hotel in New York City. Dominic P. B...
Mar 2, 2006
SAN DIEGO, Feb 02, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the underwriters have exercised an over-allotment option to purchase an additional 885,016 shares of its common stock in connection with its follow-on stock offering that priced on January 26, 2006. Inclu...
Mar 2, 2006
SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the Cowen & Co. 26th Annual Health Care Conference on Tuesday, March 7, 2006, at 11:20 a.m. Eastern Time (8:20 a.m. Pacific Time) at the Boston Marriott Copley Place, Boston, Massachusetts. Robert E. Hoffma...
Feb 8, 2006
SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the BIO CEO & Investor Conference on Tuesday, February 14, 2006, at 2:30 p.m. Eastern Time (11:30 a.m. Pacific Time) at the Waldorf Astoria, New York, New York. Louis J. Scotti, Arena's Vice President, Marke...
Feb 7, 2006
SAN DIEGO, Feb 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil, Inc., a Johnson & Johnson company, initiated a Phase 1 clinical trial of APD668, a novel orally administered drug candidate discovered by Arena for the treatment of Type 2 diabetes. The ...
Feb 2, 2006
SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday, February 9, 2006, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time) at the Grand Hyatt Hotel, New York, New Yor...
Jan 27, 2006
SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 9,752,508 shares of its common stock at a public offering price of $16.90 per share. All of the shares are being offered by the company. The underwriters have a 30-day option to purchase up to 1,...
Jan 17, 2006
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it plans to publicly offer 8,500,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. In connection with this offering, Arena plans to grant ...
Jan 5, 2006
SAN DIEGO, Jan 05, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the JPMorgan 24th Annual Healthcare Conference on Thursday, January 12, 2006, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco, Califo...
Jan 3, 2006
SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Robert E. Hoffman, C.P.A., as Chief Financial Officer. Mr. Hoffman has been with Arena since its founding in 1997, and will continue to head Arena's financial group as the company's principle financial and accounting...
Dec 29, 2005
SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was granted patent number 1558582, entitled "Diaryl and Arylheteroaryl Urea Derivatives as Modulators of the 5-HT2A Serotonin Receptor Useful for the Prophylaxis and Treatment of Disorders Related Thereto," by the European Pate...
Dec 29, 2005
SAN DIEGO, Dec. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it is advancing APD791 into preclinical development from its cardiovascular research program, and expects to initiate clinical development in approximately one year. APD791 is a selective inverse agonist of the 5-HT2A serotonin r...
Dec 13, 2005
SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from its Phase 2b clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. Over the 12 week treatment period, there was a highly statistically ...
Dec 12, 2005
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that their lead compound for the treatment of obesity, APD356, won San Diego based CONNECT's Most Innovative New Product ("MIP") Award in the Biotechnology Research and Development category. APD356 is a selective agonist of 5-HT2C ser...
Nov 2, 2005
SAN DIEGO, Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Tuesday, November 8, 2005, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time) at the New York Palace Hotel in New Y...
Nov 2, 2005
SAN DIEGO, Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the CIBC World Markets 16th Annual Healthcare Conference on Tuesday, November 8, 2005, at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time) at the Waldorf-Astoria in New York City. Jack ...
Oct 18, 2005
SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that data from its positive Phase 2a clinical trial studying APD356 in 352 obese patients was the subject of a presentation by Steven Smith, M.D., Principal Investigator and Associate Professor of the Pennington Biomedical Research Cen...
Oct 12, 2005
SAN DIEGO, Oct. 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the 2005 BIO InvestorForum on Wednesday, October 19, 2005, at 10:20 a.m. Pacific Time (1:20 p.m. Eastern Time) at The Palace Hotel in San Francisco, California. Jack Lief, Arena's President and Chief Executive ...
Oct 11, 2005
SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was issued US patent number 6,953,787, entitled "5-HT2C Receptor Modulators," by the United States Patent and Trademark Office. The patent relates to novel compounds that modulate the 5-HT2C serotonin receptor, which helps reg...
Sep 22, 2005
SAN DIEGO, Sept 22, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 28, 2005, at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at The Grand Hyatt in New York City. Jack Lief, Arena's Pr...
Sep 1, 2005
SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company will be presenting at five investor conferences during September 2005 during which it will present a corporate overview of the company and its clinical development and discovery programs. The conference information is...
Aug 25, 2005
SAN DIEGO, Aug 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that an assessment of follow-up echocardiograms taken approximately 90 days after patients received their first doses of APD356 in its Phase 2a clinical trial indicates no apparent drug effect on heart valves or pulmonary a...
Aug 11, 2005
SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was granted patent number 1133559, entitled "HUMAN ORPHAN G PROTEIN-COUPLED RECEPTOR RUP3," by the European Patent Office. The patent relates to certain drug screening methods utilizing the 19AJ receptor, an orphan G protein-c...
Jul 26, 2005
SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. initiated a Phase 1 clinical trial of an orally administered drug candidate being developed in partnership with Merck for the treatment of atherosclerosis and related disorders. The initiation of the Phase 1...
Jun 30, 2005
SAN DIEGO, June 30, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today top-line results from its Phase 1 clinical trials of APD125, Arena's orally administered, internally discovered drug candidate for the treatment of insomnia. APD125 was well tolerated at all doses investigated. The data ...
Jun 23, 2005
SAN DIEGO, June 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it started dosing patients in a Phase 2b clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. The trial will evaluate safety and weight loss in approximately 40...
Jun 17, 2005
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will present an abstract entitled "The Selective Serotonin 5-HT2A Inverse Agonist APD125 Promotes Sleep Onset and Consolidation" at the Associated Professional Sleep Societies (APSS) meeting in Denver on June 22, 2005. ...
Jun 17, 2005
SAN DIEGO, June 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and CEO, will participate in a panel entitled "Sustaining a Burn: Strategies to Fund Pipeline Development" at the BIO 2005 Annual International Convention in Philadelphia, PA, on Wednesday...
Jun 7, 2005
SAN DIEGO, June 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was issued U.S. patent number 6,902,902, entitled "Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders," by the U.S. Patent Office. The patent relates to certain...
May 26, 2005
SAN DIEGO, May 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its New York City Analyst and Investor Day will be webcast live on Thursday, June 2, 2005, at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Jack Lief, President and Chief Executive Officer, Dominic P. Behan, Ph.D...
May 19, 2005
SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will present a corporate update at the Fourth Annual Needham Biotechnology Conference on Wednesday, May 25, 2005, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Dominic P. Behan, Ph.D., Senior Vice President and Chief Scie...
May 11, 2005
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from its Phase 2 clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. Over the 28 day treatment period, there was a highly statistically sig...
May 4, 2005
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was granted patent number 03 718 323, entitled "5-HT2C Receptor Modulators," by the European Patent Office. The patent relates to novel compounds that modulate the 5-HT2C serotonin receptor, which is thought to be involved in th...
Mar 29, 2005
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will present a corporate update at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Monday, April 4, 2005, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Jack Lief, President and ...
Feb 8, 2005
SAN DIEGO, Feb 08, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the exercise in full by the underwriters of an over-allotment option to purchase 1,125,000 shares of common stock in connection with its follow-on stock offering that priced on February 1, 2005. Including the over-allotment...
Feb 1, 2005
SAN DIEGO, Feb 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 7,500,000 shares of its common stock at a public offering price of $6.00 per share. All of the shares are being offered by the company. The underwriters have a 30-day option to purcha...
Jan 18, 2005
SAN DIEGO, Jan 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has appointed Louis J. Lavigne, Jr., Executive Vice President and Chief Financial Officer of Genentech, Inc., to its board of directors. Mr. Lavigne adds further depth and expertise to Arena's board. "The...
Jan 13, 2005
SAN DIEGO, Jan. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it plans to publicly offer 6,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. In connection with this offering, Arena plans to grant ...
Dec 23, 2004
SAN DIEGO, Dec 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will receive $5.0 million in milestone payments under the recently announced collaboration with Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company. Two Arena-discovered compounds have been selected ...
Dec 22, 2004
SAN DIEGO, Dec. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has started dosing patients in a Phase 2 clinical trial of APD356, an orally administered small molecule designed to regulate satiety for the treatment of obesity. This compound is a selective agonist of 5-HT2C serotonin recep...
Dec 21, 2004
SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into a world-wide collaboration and licensing agreement with Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company, to further develop compounds for the potential treatment of type 2 diabetes and other ...
Dec 1, 2004
SAN DIEGO, Dec 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it initiated dosing in a Phase 1 clinical trial for APD125, its novel drug candidate for the treatment of insomnia and the second Arena-discovered compound to enter the clinic this year. The single-dose protocol should...
Nov 30, 2004
SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity. APD356 is a selective agonist of 5-HT2C s...
Nov 16, 2004
SAN DIEGO, Nov 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will present a corporate update at the Granite Financial Group Healthcare Investors Conference on Thursday, November 18, 2004, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time). Dominic P. Behan, Ph.D., Chief Scie...
Nov 3, 2004
SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity. APD356 is a selective agonist of 5-HT2C s...
Oct 21, 2004
SAN DIEGO, Oct. 21 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on Tuesday, October 26, 2004 at 10:50 a.m. Eastern Time (7:50 a.m. Pacific Time). Louis J. Scotti, Vice President, Marketing and Business Devel...
Oct 20, 2004
SAN DIEGO--(BUSINESS WIRE)--Oct. 11, 2004--Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the company will present a corporate update at the 2004 BIO Emerging Company Investor Forum on Thursday, October 14, 2004 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Louis J. Scotti, Vice President, Marketing and Business De...
Oct 20, 2004
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Merck & Co., Inc. has extended and increased the funding of research under their existing cardiovascular collaboration until October 2007, and expanded the scope of the collaboration to include a wider range of potential thera...
Oct 20, 2004
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that they have achieved a pre-clinical development milestone under their collaboration with Merck & Co., Inc., which triggered a $1 million payment to Arena. The Merck-Arena collaboration focuses primarily on identifying compounds...
Sep 22, 2004
SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, President and Chief Executive Officer, is scheduled to present a corporate update at the UBS Global Life Sciences Conference on Wednesday, September 29, 2004. The presentation is scheduled to take place at 4:00 p.m. E...
Sep 15, 2004
SAN DIEGO, Sep 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Harry F. Hixson, Jr., Ph.D. and Tina S. Nova, Ph.D. to the company's board of directors. Drs. Hixson and Nova add further depth to Arena's board by bringing knowledge and experience gained through execut...
Sep 14, 2004
SAN DIEGO--(BUSINESS WIRE)--Sept. 14, 2004--Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today that Jack Lief, President and Chief Executive Officer, is scheduled to present a corporate update at the Merriman Curhan Ford & Co. Investor Summit 2004 on Monday, September 20, 2004. The presentation is scheduled to take place at 2:...
Aug 31, 2004
SAN DIEGO, Aug. 13 /PRNewswire/ -- Arena Pharmaceuticals (Nasdaq: ARNA) will present a corporate update at the following forum: What: Arena Pharmaceuticals will give a presentation at Informed Investors Healthcare Virtual Stocks Forum Robin R. Young, CFA, Managing Director, Research Healthpoint
Aug 10, 2004
SAN DIEGO, Aug 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the achievement of a $3 million milestone from Merck & Co., Inc. for assay development under their cardiovascular collaboration. In October 2002, Arena and Merck entered into a collaboration focused on a group...
Jul 26, 2004
SAN DIEGO, Jul 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has initiated a Phase 1b clinical trial of APD356, its 5-HT2C selective, lead anti-obesity compound. The purpose of this Phase 1b study is to evaluate safety at steady state drug levels during 14-day repeated daily...
Jul 14, 2004
SAN DIEGO, Jul 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from a Phase 1a, single-dose clinical trial of the company's novel anti-obesity compound, APD356. APD356 is an orally administered small molecule that is a selective 5-HT2C serotonin receptor agonist. The 5-HT2C r...
Jun 14, 2004
SAN DIEGO, June 14 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, President and Chief Executive Officer, is scheduled to present a corporate update at the Needham & Company Third Annual Biotechnology Conference on Thursday, June 17, 2004. The presentation is scheduled to take pla...
May 6, 2004
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Dominic Behan, Vice President, Research and co-founder of Arena, is scheduled to present a corporate update at the Rodman & Renshaw Techvest Global Healthcare Conference on Wednesday, May 12, 2004. The presentation is scheduled...
Apr 26, 2004
SAN DIEGO, Apr 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, President and Chief Executive Officer, is scheduled to present a corporate update at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Wednesday, April 28, 2004. The pr...
Mar 17, 2004
SAN DIEGO, Mar 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of William R. Shanahan, Jr., M.D., J.D. as Vice President, Chief Medical Officer, effective March 29, 2004, to head its clinical development operations. "As we transition from discovery research and...
Feb 25, 2004
SAN DIEGO, Feb 25, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the achievement of a $4 million milestone related to animal testing of small molecules that act upon selected G protein-coupled receptors (GPCRs), which may represent novel targets for cardiovascular disease. Arena and Mer...
Feb 24, 2004
SAN DIEGO, Feb 24, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has initiated a Phase 1 clinical trial in the United Kingdom for APD356, its lead anti-obesity compound. This double-blind, placebo-controlled, single-dose, dose-escalation trial is planned to enroll 54 healthy, ove...
Jan 8, 2004
SAN DIEGO, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will release its financial results for the fourth quarter and full year of 2003 after the NASDAQ National Market closes on Tuesday, January 20, 2004, and will host both a telephone and Internet fourth quarter conference ...
Jan 5, 2004
SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the resignation of its Chief Financial Officer, Joseph F. Mooney. Arena's Vice President, Finance, Robert E. Hoffman, will continue to serve as its chief accounting officer. Jack Lief, Arena's President and Chief Executive O...
Dec 24, 2003
SAN DIEGO, Dec. 24 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed the private placement of $35 million of Series B-1 Convertible Preferred Stock to two institutional investors. Arena expects to use the net proceeds from the financing for working capital and general corporate purposes....
Dec 16, 2003
SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointments of Donald D. Belcher, Scott H. Bice and Robert L. Toms as members of its Board of Directors and Frederick Frank as an Advisory Director to its Board of Directors. Mr. Bice is replacing Mark Lampert as the BVF Designee...
Dec 15, 2003
SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has successfully completed preclinical studies on its internally discovered compound for obesity, APD356, and remains on schedule to initiate Phase I human clinical trials in the first quarter of 2004. Arena also announced that...
Oct 31, 2003
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Derek T. Chalmers, Ph.D., Vice President, Research and Director of Arena Pharmaceuticals, Inc., will present at the CIBC World Markets 14th Annual Healthcare Conference at the Plaza Hotel in New York City on Tuesday, November 11, ...
Oct 20, 2003
SAN DIEGO, Oct 20, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Biotechnology Value Fund, L.P. and certain of its affiliates accepted Arena's offer to purchase three million shares of Arena common stock from them at a cash price per share of $7.69. Arena made the offer on October ...
Oct 8, 2003
SAN DIEGO, Oct 8, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Stockholders Agreement dated as of January 17, 2003, with its largest stockholder, Biotechnology Value Fund, L.P. and certain related entities ("BVF"), has been amended, and that the parties are in discussions about...
Sep 5, 2003
SAN DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Jack Lief, President and Chief Executive Officer of Arena Pharmaceuticals, Inc., will present at the UBS Global Life Sciences Conference at the Plaza Hotel in New York City on Wednesday, September 24, 2003, at 11:00 a.m. EDT (8:00...
May 30, 2003
SAN DIEGO, May 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Derek T. Chalmers, Ph.D., Vice President, Research and Director of Arena Pharmaceuticals, Inc., will present at the Needham & Company Second Annual Biotechnology Conference at the New York Palace Hotel on Friday, June 6, 2003, at...
Apr 30, 2003
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Patent and Trademark Office issued Arena a patent entitled "Non-Endogenous, Constitutively Activated Human Protein Coupled Receptors." This patent, U.S. Patent Serial No. 6,555,339, covers one of Arena's proprietary method...
Nov 13, 2002
SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. ("Arena") (Nasdaq: ARNA) announced today that the three-year research collaboration between Arena and Eli Lilly and Company ("Lilly") will not continue after April 14, 2003. The principle objective of the research collaboration is the activation and enablement of...
Oct 31, 2002
SAN DIEGO, Oct 31, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. ("Arena") (Nasdaq: ARNA) announced that on October 30, 2002, its Board of Directors approved the adoption of a Stockholders Rights Plan under which all stockholders of record as of November 13, 2002, will receive rights to purchase shares of a new series of...
Oct 28, 2002
SAN DIEGO, Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointments of Dr. J. Clayburn La Force, Jr., and Dr. Duke K. Bristow to the company's Board of Directors. The new directors have been appointed to fill the vacancies created by the resignations of Dr. John P. McAlister I...
Oct 16, 2002
SAN DIEGO, Oct 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) (Arena) announced today that it has entered into a multi-year research and licensing agreement with Merck & Co., Inc. (Merck) to collaborate on validating and developing therapeutics on three orphan G protein-coupled receptors (GPCRs) of ...
Sep 30, 2002
SAN DIEGO, Sep 30, 2002 (BUSINESS WIRE) -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), announced today that it will host both a telephone and internet third quarter conference call on Tuesday, October 29, 2002 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). The Company will release financial results for the third quarter that afternoon af...
May 28, 2002
SAN DIEGO, May 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of a research and license agreement with Ferring Pharmaceuticals, Inc. (Ferring), a unit of privately-held Ferring Holding S.A., a biopharmaceutical company with operations in 35 countries and products di...
Apr 4, 2002
SAN DIEGO, Apr 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet first quarter conference call on Wednesday, April 24, 2002 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph ...
Nov 7, 2001
SAN DIEGO, Nov. 7 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has completed its initial analysis of human G protein-coupled receptor (GPCR) gene expression in 80 normal human tissues. Utilizing a proprietary, custom-designed, oligonucleotide "GPCR chip," Arena has identified relative expression l...
Aug 31, 2001
SAN DIEGO, Aug 31, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet conference call on Wednesday September 5, 2001 at 4:15 p.m. Eastern Time (1:15 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial officer...
Aug 20, 2001
SAN DIEGO, Aug 20, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA); ("Arena") today announced the signing of a license agreement with TaiGen Biotechnology Co., Ltd. ("TaiGen"), a privately-held biopharmaceutical organization located in Taipei, Taiwan. Under the terms of the agreement, TaiGen has the right to select validated scr...
Jul 9, 2001
SAN DIEGO, July 9 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with the ICI group to apply Arena's proprietary CART technology to olfactory and gustatory G protein-coupled receptors (GPCRs). The initial stage of the research will last at least six months and Arena int...
Jul 5, 2001
SAN DIEGO, Jul 5, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet second quarter conference call on Monday, July 23, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial...
Jul 2, 2001
SAN DIEGO, Jul 2, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriting group managed by Thomas Weisel Partners LLC, Dain Rauscher Wessels, ABN AMRO Rothschild LLC and Lazard Freres & Co. LLC., have exercised their over-allotment option in connection with Arena's June 21, 2001 secondary offeri...
Jun 22, 2001
SAN DIEGO, June 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its follow-on offering of 5,000,000 shares of its common stock was priced on June 21, 2001 at $27.50 per share. Of the 5,000,000 shares, Arena offered 4,000,000 shares and two selling stockholders offered a total 1,000,000 shares. Arena...
Jun 5, 2001
SAN DIEGO, June 5 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed follow-on offering of 5,000,000 shares of its common stock. Of the 5,000,000 offered shares, Arena will offer 4,000,000 shares and two sellin...
May 8, 2001
NEW YORK--(BUSINESS WIRE)--May 8, 2001--The Wall Street Transcript has published an in-depth interview with Jack Lief, CEO of Arena Pharmaceuticals (Nasdaq:ARNA), in which he talks at length about the company's future. Click here to listen to a live webcast for the RBC Dain Rauscher Wessels Biotechnology "Gene To Drugs"...
Apr 25, 2001
SAN DIEGO--(BW HealthWire)--April 25, 2001-- The Collaborative Research Program Will Begin Immediately, and Arena's Purchase of $2 Million of Axiom Preferred Stock Expected to be Completed by the End of May 2001 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Axiom Biotechnologies Inc. ("Ax...
Apr 17, 2001
SAN DIEGO, April 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended March 31, 2001. During the first quarter 2001, the Company's revenues increased by $1.3 million over the previous quarter to record revenues of $5.4 million versus no revenues for the first quarter of 2000. Reve...
Mar 26, 2001
SAN DIEGO, March 26 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has entered into a receptor-discovery research collaboration with Taisho Pharmaceutical Co., Ltd. Phase I of the collaboration is directed toward identification studies for a receptor of interest to Taisho. Although the endogenous l...
Feb 20, 2001
SAN DIEGO, Feb. 20 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the completion of the acquisition of the outstanding capital stock of Bunsen Rush Laboratories, Inc. via merger with Arena's wholly-owned subsidiary, BRL Screening, Inc. BRL Screening is a Delaware corporation headquartered in San D...
Jan 31, 2001
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of an expansion amendment to its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho") by which Taisho has received world-wide rights to Arena's 18F Program. In addition to potential future mile...
Jan 15, 2001
SAN DIEGO, Jan. 15 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly and Company (NYSE: LLY), Arena has received $1.5 million in milestone payments from Lilly in the fourth quarter of 2000. These milestone pa...
Dec 27, 2000
SAN DIEGO and DALLAS, Dec. 27 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Bunsen Rush Laboratories, Inc. ("Bunsen Rush"), a privately-held corporation, today jointly announced the signing of a Binding Letter of Intent & Memorandum of Agreement ("Agreement") for Arena to acquire all of the outstanding ca...
Nov 29, 2000
SAN DIEGO, Nov. 29 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of a Notice of Allowance ("Allowance") from the United States Patent and Trademark Office directed to a method of identifying inverse agonists to a CART-activated human serotonin receptor. An Allowance indicates that all of the r...
Oct 23, 2000
SAN DIEGO, Oct. 23 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd., Arena has achieved several financial research and development milestones. These milestones are related to acceptance by Taisho of a CART-activat...
Sep 25, 2000
SAN DIEGO, Sept. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly and Company, Arena has received its first research milestone payments from Eli Lilly. These milestone payments are related to acceptance b...
Aug 22, 2000
SAN DIEGO, Aug. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of United States Patent Number 6,107,324 entitled "Non-Endogenous Constitutively Activated Human Serotonin Receptors and Small Molecule Modulators Thereof." This is the first patent issued to Arena since its inception in April of...
Aug 10, 2000
SAN DIEGO, Aug. 10 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriters led by ING Barings LLC, Prudential Securities Incorporated, and SG Cowen Securities Corporation, have exercised in full their over-allotment option in connection with Arena's initial public offering, and purchased an addi...
Aug 1, 2000
THE WOODLANDS, Texas, Aug. 1 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) today announced the formalization of a joint research collaboration with Arena Pharmaceuticals (Nasdaq: ...
Jul 28, 2000
SAN DIEGO, July 28 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its initial public offering of 6,000,000 shares of its common stock was priced at $18 per share, above the initial filing range of $15-$17 per share. All of the shares are being sold by Arena. The shares will be offered through an underw...
Jul 28, 2000
NEW YORK, July 28 (Reuters) - The initial public offering market has regained the pizazz that made it famous during its heyday last year -- at least for now.While the technology-rich Nasdaq composite index (^IXIC - news...
Jul 28, 2000
July 28, 2000--Arena Pharmaceuticals, Inc. (Nasdaq:ARNA - news) was admitted to the Nasdaq National Market System following its initial public offering of 6 million shares at $18 per share. The company's stock trades under the ticker symbol ARNA. Company address: 6...
Jul 27, 2000
NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq:ARNA - news) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the...
Jul 25, 2000
WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares.The company, which says it has developed technology that identifies drug candidates more efficiently that traditional techniques,...
Jun 22, 2000
WASHINGTON, June 22 (Reuters) - Arena Pharmaceuticals Inc., which says it has found a new way of finding new drug candidates more efficiently, on Thursday said it will offer five million shares in a projected price range of $15-$17 per share when it goes public.It expects to raise about $73...
Apr 17, 2000
INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening targets, utilizing Arena's proprietary CART™...
Jan 31, 2000
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have entered into a collaboration involving Arena's proprietary CART™ Technology...